Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer
about
Re-Use of Established Drugs for Anti-Metastatic IndicationsSympathetic nervous system regulation of the tumour microenvironmentThe Clinical Relevance of Beta Blockers in Ovarian Carcinoma: A Systematic ReviewHistory of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium.Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.Reducing liver metastases of colon cancer in the context of extensive and minor surgeries through β-adrenoceptors blockade and COX2 inhibitionBevacizumab induced hypertension in gynecologic cancer: Does it resolve after completion of therapy?Role of sympathetic nerves in the establishment of metastatic breast cancer cells in boneHypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer.NO-dependent attenuation of TPA-induced immunoinflammatory skin changes in Balb/c mice by pindolol, heptaminol or ATRA, but not by verapamil.Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancerPostdiagnostic use of β-blockers and other antihypertensive drugs and the risk of recurrence and mortality in head and neck cancer patients: an observational study of 10,414 person-years of follow-up.β-adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8(+) T cells and undermines checkpoint inhibitor therapy.β-Adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives.Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study.Pre- and post-diagnostic beta-blocker use and prognosis after colorectal cancer: Results from a population-based study.Essential Neuroscience in Immunology.Commonly used medications and endometrial cancer survival: a population-based cohort study.Association of Ovarian Tumor β2-Adrenergic Receptor Status with Ovarian Cancer Risk Factors and Survival.Beta-adrenergic receptors are expressed across diverse cancers.ACT-ONE - ACTION at last on cancer cachexia by adapting a novel action beta-blocker.Altered uterine contractility in response to β-adrenoceptor agonists in ovarian cancer.Effect of postoperative analgesia technique on the prognosis of gastric cancer: a retrospective analysis.To block it, or not to block it?Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management.Neuroimmune Interactions: From the Brain to the Immune System and Vice Versa.β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer.The Impact of Housing Temperature-Induced Chronic Stress on Preclinical Mouse Tumor Models and Therapeutic Responses: An Important Role for the Nervous System.Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice.Non-selective beta blockers inhibit angiosarcoma cell viability and increase progression free- and overall-survival in patients diagnosed with metastatic angiosarcoma.The effects of beta-blocker use on cancer prognosis: a meta-analysis based on 319,006 patientsβ-Adrenergic receptor modulates mitochondrial metabolism and disease progression in recurrent/metastatic HPV(+) HNSCCImaging Mass Spectrometry Reveals Crosstalk between the Fallopian Tube and the Ovary that Drives Primary Metastasis of Ovarian CancerPropranolol for the treatment of vascular sarcomasVisualizing Ligand Binding to a GPCR In Vivo Using NanoBRET
P2860
Q26771704-AEBE272A-5F0F-4D2D-9355-B7E52DB8391DQ26795614-F03060CD-D4F0-429C-AED0-F154E83B6AA6Q28074666-AD4DD167-1CF1-469D-A122-EDBE6CDF2C32Q30252952-AD2DCD9C-ECEC-47CA-A2F6-00915A4076D7Q33865098-E819D8F8-A0A1-41A1-900D-7C5E149F530EQ33871656-9B73783B-0751-4569-A233-C7CFCC0E7903Q37215966-3E409F7B-2B55-4596-B433-0B1461D7A87BQ37337499-69581C1B-FDD8-4891-A1D1-6937DAE4DA0EQ37409359-5BBE0077-9A4B-4413-9827-EC65FE98135DQ37565209-75364200-4E7A-4668-B11A-7543B2B654C1Q37701617-EE7B7864-67A4-4A7D-ACD9-6651B7F055A6Q38406732-17C8AD4C-9AD3-4474-AF61-B21B9C729155Q38619196-CC227392-C055-4B19-921D-0F0D29D64588Q38742275-881FA78B-E637-4D9B-8300-FBEC4F67EFB7Q38777059-6CE6B131-554A-4819-9026-38F2F3C8D774Q38859607-FCE62636-02CC-4391-9A33-72DC17599A02Q39247074-2AA070C2-B9F5-47AB-ABEF-F188CA6D5E3DQ40132826-DB2D8075-4833-4498-AFFB-252EC2EDF70CQ40597334-B1A08F20-F65C-4D61-BA9D-2BEB9B475846Q41667468-203BFC5B-95E7-41A3-A728-165DF3BAF465Q42398016-2A9D7729-316D-4B97-9A77-CE8D310E8433Q42702699-5A091604-A47A-42F0-BF0C-5F7B145DF577Q47114710-D74CFEE2-EB70-4CD2-81C6-8AB76D126EB8Q47150265-8A75E773-689C-4434-854C-C030B9CE47A8Q47566245-B2854F86-38EF-4536-8DEE-DA6E1D59B415Q47851508-33E6FA50-D8EC-47A9-B6A7-B67C414E5DE8Q47911126-FC6A910C-7BB7-42A5-98B8-FA8A15254823Q49592840-A223CBF9-C56B-49D5-8580-5DC3D8D7C76AQ50535266-B48B5CD9-3303-4407-820E-3A8657750C99Q55192373-DCDAF320-6447-4B0A-A976-75782B51BC48Q57168537-9BA228B5-D862-4692-9535-BACDE49D44CAQ57295721-DA637A8A-828B-40B6-86E6-81C3706863BBQ58564653-31EFAC2C-BF58-4592-9836-0E3504E0157DQ58761654-76E018EA-7F33-4FE8-9AF9-0E91760D32CBQ58788212-62D25CA4-700A-4234-A31E-FE26F43FA18B
P2860
Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Clinical impact of selective a ...... n patients with ovarian cancer
@ast
Clinical impact of selective a ...... n patients with ovarian cancer
@en
Clinical impact of selective a ...... n patients with ovarian cancer
@nl
type
label
Clinical impact of selective a ...... n patients with ovarian cancer
@ast
Clinical impact of selective a ...... n patients with ovarian cancer
@en
Clinical impact of selective a ...... n patients with ovarian cancer
@nl
prefLabel
Clinical impact of selective a ...... n patients with ovarian cancer
@ast
Clinical impact of selective a ...... n patients with ovarian cancer
@en
Clinical impact of selective a ...... n patients with ovarian cancer
@nl
P2093
P2860
P356
P1433
P1476
Clinical impact of selective a ...... n patients with ovarian cancer
@en
P2093
Alpa M Nick
Anil K Sood
Diana L Urbauer
Jack L Watkins
Kathryn C Squires
Lois M Ramondetta
Pedro T Ramirez
Premal H Thaker
Robert L Coleman
Sanjeev Kumar
P2860
P304
P356
10.1002/CNCR.29392
P407
P50
P577
2015-08-24T00:00:00Z